Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil

Steven Vernino, Diva R. Salomao, Thomas M. Habermann, Brian P. O'Neill

Research output: Contribution to journalArticle

56 Scopus citations


Mycophenolate mofetil (MM), an immunosuppressant used after organ transplantation, is also used for treatment of autoimmune myasthenia gravis (MG). A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment. Primary CNS lymphoma regressed on withdrawal of MM. Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with MM may be associated with increased risk of lymphoproliferative disorders.

Original languageEnglish (US)
Pages (from-to)639-641
Number of pages3
Issue number4
StatePublished - Aug 23 2005


ASJC Scopus subject areas

  • Clinical Neurology

Cite this